先端生物医学研究とイノベーション

Prevention of Kernicterus and Lowering the Incidence of Cerebral Palsy- An Upliftment of Rural Health Care In India

Asish Bhakta and Anjan Bhattacharya

Kernicterus is a bilirubin induced brain dysfunction that results from unconjugated hyperbilirubinemia in a newborn. It can cause athetoid cerebral palsy, hearing loss and sometimes intellectual disabilities. Cerebral palsy is the leading cause of childhood disability affecting function and development. [1] The incidence of the condition has not changed in more than 4 decades. [2] Population-based studies from around the world report prevalence estimates of CP ranging from 1.5 to more than 4 per 1,000 live births. [3] In India, the estimated incidence is around 3/1000 live births. [4] About 60% of full-term newborns and 80% of premature babies get jaundice. [5] Hypoxic Ischemic Encephalopathy and bilirubin encephalopathy (Kernicterus) are the principle causes of Athetoid Cerebral Palsy. Phototherapy and Exchange transfusion remains the only effective therapy to prevent development of bilirubin encephalopathy. These treatment modalities were not available in rural areas of India in the past. But over last 10 to 15 years, these technologies along with Lab and imaging facilities are being widely used in the periphery as a result of which the incidence of kernicterus and athetoid cerebral palsy has dropped significantly in the rural areas including my own. We share our experience of effectively treating neonatal hyperbilirubinemia in our peripheral setup.